
PTCT PTC Therapeutics, Inc.
- Analyst targetsLow confidence6 analysts$104+84%Range $75–$137Typical for this method across large companies: +20%
- Value at the industry multipleNext year's earnings × 19.9, median of 62 companies$37−34%Range $21–$75
- Discounted cash flow modelLow confidence8.6% discount rate · 9% growth a year$20−65%Range $20–$20Typical for this method across large companies: −39%
The floor: what the company is worth if growth stopped today
- Value with no growthToday's after-tax operating profit, held flat forever, at a 8.6% discount rate$35−38%
38% of today's price is what a buyer pays for growth that has not happened yet.
- 1
- methods value it above the price
- 0
- methods near the price
- 2
- methods value it below the price
10-year US Treasury yield 5.04% as of 2026-11-19. Estimates computed from company data and analyst targets, not investment advice.
Get Your Premium Account Now
- Stock Deep Analysis
- The Advanced News Platform
The company reports in USD. Forecast amounts use the data provider’s units.
Quarterly estimates
Fiscal period end
Last refreshed
- EPS Estimate
- 0.3468
- Range -1.3558 – 1.8918
- Analysts 3
- Revenue Estimate
- 330.38M
- Range 309.5M – 349.54M
- Analysts 8
Fiscal period end
Last refreshed
- EPS Estimate
- 0.4589
- Range 0.269 – 0.6487
- Analysts 4
- Revenue Estimate
- 312.36M
- Range 290.83M – 333.88M
- Analysts 3
Fiscal period end
Last refreshed
- EPS Estimate
- 0.5434
- Range 0.4933 – 0.5908
- Analysts 1
- Revenue Estimate
- 332.96M
- Range 309.35M – 355.31M
- Analysts 1
Fiscal period end
Last refreshed
- EPS Estimate
- 0.534
- Range 0.4848 – 0.5806
- Analysts 1
- Revenue Estimate
- 343.66M
- Range 319.29M – 366.73M
- Analysts 1
Annual estimates
Fiscal period end
Last refreshed
- EPS Estimate
- 0.5261
- Range -0.3156 – 0.9995
- Analysts 7
- Revenue Estimate
- 1.32B
- Range 1.3B – 1.34B
- Analysts 10
Fiscal period end
Last refreshed
- EPS Estimate
- 2.7301
- Range 1.4163 – 4.2396
- Analysts 7
- Revenue Estimate
- 1.43B
- Range 1.33B – 1.56B
- Analysts 10
Fiscal period end
Last refreshed
- EPS Estimate
- 4.3808
- Range 1.4786 – 8.8848
- Analysts 11
- Revenue Estimate
- 1.63B
- Range 1.3B – 2.05B
- Analysts 12
Which listings have analyst coverage?
EL7 refreshes analyst ratings and price targets for active company listings on Nasdaq, the New York Stock Exchange and NYSE American, including US-listed depositary receipts. Funds (including ETFs and mutual funds), OTC listings and listings on other exchanges are outside this coverage. Some eligible listings may have no published target or analyst call in the past 12 months.
EL7 checks for new ratings several times on weekdays, refreshes consensus targets on weekdays and updates monthly rating history once a month.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
- P/E (TTM)——
- Forward P/E29.96x4.63x37.03xNear median
- EV / EBITDA15.42x3.71x29.64xCheap
- FCF Yield0.0%-99.3%7.8%Strong
- Revenue Growth YoY-35.1%-48.8%73.2%Below average
- EPS Growth YoY-116.4%-103.1%98.8%Weak
- Gross Margin92.4%15.1%89.4%Exceptional
- ROIC37.3%-150.5%16.1%Exceptional
- Net Debt / EBITDA-7.16x0.00x1.99xNet cash
- Dividend YieldPays no dividend—
- Payout RatioPays no dividend—
- Altman Z-Score0.72-17.7515.77Above average
Frequently Asked Questions
What is PTC Therapeutics, Inc. stock?▼
PTC Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
How can I invest in PTC Therapeutics, Inc.?▼
You can buy PTC Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
What are the key metrics for evaluating PTC Therapeutics, Inc.?▼
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Does PTC Therapeutics, Inc. pay dividends?▼
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
What are the risks of investing in PTC Therapeutics, Inc.?▼
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.